Effect Of Huazhuo Method On Monocyte Subsets And TLR4 Expression In Patients With Coronary Heart Disease With Phlegm Turbidity Syndrome

Objective:To observe the clinical efficacy and side effects of Huazhuo method(Huazhuo formula)in the treatment of coronary heart disease(phlegm turbidity syndrome),and the expression of monocyte subsets CD14++CD16-(mol),CD14++CD16+(mo2),CD14+CD16+(Mo3)and their surface marker TLR4,and to explore the clinical effect of Huazhuo method(Huazhuo formula)in the treatment of coronary heart disease(phlegm turbidity syndrome)Objective to investigate the effect of Huazhuo Decoction(Huazhuo Decoction)on the expression of monocyte subsets and TLR4 in patients with heart disease(phlegm turbidity syndrome),and to study the possible immune mechanism of Huazhuo method(Huazhuo formula)in the treatment of coronary heart disease(phlegm turbidity syndrome)Methods:60 patients with coronary heart disease were chosed as the objects,we divide them into two groups randomly,each group included 30 cases.The control group patients was treated by traditional western medicine such as antiplatelet aggregation,crown expansion,lipid regulation and heart rate reduction;the treatment group was treated by traditional western medicine and Huazhuo Decoction(composed of gualou,chishi,houpu,fuling,chenpi,etc.),and the drugs were added or subtracted according to different patients’ conditions.All patients were treated for two weeks,per and post-treatment,TCM syndrome score,Seattle angina pectoris scale,monocyte subsets(Mo1,Mo2,Mo3)and TLR4 expression level were used to evaluate the treatment effect.Another 30 healthy people were selected as the healthy group.The expression levels of monocyte subsets(Mo1,Mo2,Mo3)and TLR4 were detected.Result:1.General situation:in the follow-up process per and post-treatment,30 patients in the treatment group(3 cases lost)and 30 patients in control group(3 cases lost)completed the study.There were 30 cases in the healthy group,and finally 90 cases completed in this clinical study.There was no significant difference in gender and age between healthy group and disease group(P>0.05).There were no significant differences between the two groups in general information(P>0.05).2.TCM syndrome score:Comparison between the two groups:Pre-treatment,TCM syndrome score is no significant difference in two groups(P>0.05),post-treatment,the TCM syndrome score of the treatment group was lower than the control group(P<0.05).Intra group comparison:the TCM syndrome scores of the two groups after treatment were significantly lower than those before treatment,the difference was significant(P<0.01).Treatment effect:the total effective rate of the control group was 63.33%.the treatment group was 86.67%.The total effective rate of the treatment group was higher than the control group(P<0.05).3.Seattle Angina scale:Seattle Angina scale:comparison between groups:before treatment,there was no significant difference in Seattle Angina scale(PL,AS,AF,TS,DS)(P>0.05).After treatment,PL in the treatment group was higher than the control group(P<0.01),and so was DS(P<0.05).Intra group comparison:After treatment,all Seattle angina pectoris scales of the two groups were better than before(P<0.01).4.Monocyte subsets and surface marker TLR4:disease group and healthy group:the proportion of monocyte subsets Mo2 and TLR4 expression in Mo2 and Mo3 of 60 patients in disease group were higher than the healthy group(P<0.05).The proportion of Mo3 in healthy group was higher than that of disease group,the difference was statistically significant(P<0.05),while there was no significant difference in the proportion of Mo1 and the expression of TLR4 in Mo1 between the two groups(P>0.05).Treatment group and control group:Comparison between groups:Per and post-treatment,there was no significant difference in the proportion of three monocyte subsets between the two groups(P>0.05).Pre-treatment,the expression of TLR4 in three monocyte subsets has no difference between two groups(P>0.05).Post-treatment,the expression of TLR4 in monocyte subgroup Mo2 in the treatment group was lower than the control group(P<0.05).In addition,the expression of TLR4 in Mol and Mo3 has no difference between two groups(P>0.05).Intra group comparison:After treatment,the proportion of Mo2 in the treatment group was lower than before(P<0.05),and in the control group,the proportion of Mo2 has no significant difference pre and post-treatment(P>0.05).The proportion of Mol and Mo3 between the two groups has no difference pre and post-treatment(P>0.05).Compared per and post-treatment,the expression of TLR4 in monocyte subgroup Mo2 of control group and treatment group was significantly lower than that before treatment,the difference was statistically significant(P<0.05).The expression of TLR4 in monocyte subgroup Mo1 and Mo3 of control group and treatment group had no significant difference before and after treatment(P>0.05).Conclusion:1.On the basis of Western medicine treatment,Huazhuo method(Huazhuo prescription)can significantly relieve the symptoms of patients with coronary heart disease(phlegm turbidity syndrome)and improve the quality of life of patients.2.Huazhuo method(Huazhuo prescription)has no side effects,similarly,there is no serious adverse reaction in the process,the method is very safe.3、The proportion of CD14++CD 16+and the expression of TLR4 on CD 14++CD 16+in patients with coronary heart disease(phlegm turbidity syndrome)were higher than those in healthy people,which indicated that the formation of coronary heart disease(phlegm turbidity syndrome)may be related to the proportion of CD 14++CD16+and the up regulation of TLR4 expression on CD14++CD16+.4.Huazhuo method(Huazhuo prescription)can effectively reduce the expression level of CD14++CD 16+and TLR4 in patients with coronary heart disease(phlegm turbidity syndrome).Its effective mechanism may be related to inflammatory response,regulation of immune factors and regulation of immune function.